vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $9.4M, roughly 1.7× Broadway Financial Corp). Broadway Financial Corp runs the higher net margin — 1934.0% vs -7.8%, a 1941.7% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 10.1%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 9.7%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
BYFC vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.4M | $16.1M |
| Net Profit | $1.0M | $-1.2M |
| Gross Margin | — | — |
| Operating Margin | — | -2.8% |
| Net Margin | 1934.0% | -7.8% |
| Revenue YoY | 10.1% | 27.3% |
| Net Profit YoY | -21.8% | -182.0% |
| EPS (diluted) | $0.02 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | $16.1M | ||
| Q3 25 | $9.0M | $17.0M | ||
| Q2 25 | $8.1M | $15.0M | ||
| Q1 25 | $8.3M | $13.1M | ||
| Q4 24 | $8.6M | $12.6M | ||
| Q3 24 | $8.7M | $14.6M | ||
| Q2 24 | $8.2M | $14.9M | ||
| Q1 24 | $7.8M | $13.0M |
| Q4 25 | $1.0M | $-1.2M | ||
| Q3 25 | $-23.9M | $-2.3M | ||
| Q2 25 | $752.0K | $-3.8M | ||
| Q1 25 | $-2.7M | $-4.1M | ||
| Q4 24 | $1.3M | $1.5M | ||
| Q3 24 | $516.0K | $-2.4M | ||
| Q2 24 | $256.0K | $-3.4M | ||
| Q1 24 | $-154.0K | $-10.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 56.0% | ||
| Q1 24 | — | 47.7% |
| Q4 25 | — | -2.8% | ||
| Q3 25 | -256.2% | -9.0% | ||
| Q2 25 | 12.8% | -19.2% | ||
| Q1 25 | -45.3% | -25.3% | ||
| Q4 24 | 21.7% | 17.7% | ||
| Q3 24 | 8.5% | -19.8% | ||
| Q2 24 | 4.8% | -19.7% | ||
| Q1 24 | -2.9% | -77.4% |
| Q4 25 | 1934.0% | -7.8% | ||
| Q3 25 | -264.2% | -13.6% | ||
| Q2 25 | 9.3% | -25.3% | ||
| Q1 25 | -32.3% | -31.0% | ||
| Q4 24 | 15.3% | 12.1% | ||
| Q3 24 | 5.9% | -16.3% | ||
| Q2 24 | 3.1% | -22.6% | ||
| Q1 24 | -2.0% | -80.1% |
| Q4 25 | $0.02 | $-0.04 | ||
| Q3 25 | $-2.86 | $-0.09 | ||
| Q2 25 | $0.00 | $-0.16 | ||
| Q1 25 | $-0.39 | $-0.18 | ||
| Q4 24 | $0.07 | $0.10 | ||
| Q3 24 | $-0.03 | $-0.12 | ||
| Q2 24 | $0.02 | $-0.17 | ||
| Q1 24 | $-0.02 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $24.1M |
| Total DebtLower is stronger | — | $25.3M |
| Stockholders' EquityBook value | $262.8M | $31.9M |
| Total Assets | $1.3B | $94.6M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | $24.1M | ||
| Q3 25 | $19.7M | $24.9M | ||
| Q2 25 | $29.5M | $20.3M | ||
| Q1 25 | $15.8M | $21.1M | ||
| Q4 24 | $61.4M | $20.3M | ||
| Q3 24 | $97.1M | $22.5M | ||
| Q2 24 | $89.8M | $23.9M | ||
| Q1 24 | $67.1M | $24.1M |
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | $262.8M | $31.9M | ||
| Q3 25 | $261.7M | $25.9M | ||
| Q2 25 | $284.7M | $19.2M | ||
| Q1 25 | $283.6M | $21.5M | ||
| Q4 24 | $285.0M | $20.1M | ||
| Q3 24 | $286.2M | $10.9M | ||
| Q2 24 | $282.1M | $11.3M | ||
| Q1 24 | $281.1M | $13.0M |
| Q4 25 | $1.3B | $94.6M | ||
| Q3 25 | $1.3B | $85.2M | ||
| Q2 25 | $1.2B | $81.2M | ||
| Q1 25 | $1.3B | $85.0M | ||
| Q4 24 | $1.3B | $80.2M | ||
| Q3 24 | $1.4B | $64.0M | ||
| Q2 24 | $1.4B | $65.2M | ||
| Q1 24 | $1.4B | $66.6M |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $-6.3M |
| Free Cash FlowOCF − Capex | $-13.0K | — |
| FCF MarginFCF / Revenue | -0.1% | — |
| Capex IntensityCapex / Revenue | 2.6% | — |
| Cash ConversionOCF / Net Profit | 0.22× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | $-6.3M | ||
| Q3 25 | $3.8M | $-2.4M | ||
| Q2 25 | $3.0M | $-942.0K | ||
| Q1 25 | $-4.3M | $-2.8M | ||
| Q4 24 | $1.4M | $2.2M | ||
| Q3 24 | $6.1M | $-1.2M | ||
| Q2 24 | $9.8M | $-5.2M | ||
| Q1 24 | $-11.7M | $-5.0M |
| Q4 25 | $-13.0K | — | ||
| Q3 25 | $3.7M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $-4.4M | — | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $6.1M | — | ||
| Q2 24 | $9.7M | — | ||
| Q1 24 | $-11.7M | — |
| Q4 25 | -0.1% | — | ||
| Q3 25 | 41.1% | — | ||
| Q2 25 | 37.0% | — | ||
| Q1 25 | -52.4% | — | ||
| Q4 24 | 14.7% | — | ||
| Q3 24 | 69.6% | — | ||
| Q2 24 | 118.9% | — | ||
| Q1 24 | -149.7% | — |
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 0.7% | — |
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.06× | 1.46× | ||
| Q3 24 | 11.85× | — | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BYFC
Segment breakdown not available.
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
